Skip to main content
. 2007 Jan;170(1):263–271. doi: 10.2353/ajpath.2007.060596

Figure 5.

Figure 5

Involvement of Treg in the therapeutic effect of AM in CIA. A: CIA mice were treated with medium (control) or with AM (2 nmol/day) for 5 days and were treated with control Ig, anti-IL-10 (αIL10), anti-TGF-β (αTGFβ), or a combination of both antibodies on alternate days starting with the first AM administration (five to seven mice per group). Severity of arthritis was assessed by clinical scoring. P < 0.001 versus Ig control treatment for αIL10 and/or αTGFβ treatments after day 37. B: CD4+ cells were isolated from DLN of CIA mice treated with medium (CD4control) or AM (CD4AM) at the peak of disease and stimulated in vitro with CII. Some samples were depleted of CD25+ cells. Cells (5 × 106) were injected intravenously into arthritic mice 2 days after disease onset (four to six mice per group). CIA mice without any treatment (untreated) were used as arthritic controls. P < 0.001 versus untreated control for CD4AM treatment after day 32. P < 0.001 versus CD4AM treatment for CD25-depleted CD4AM cells after day 35.